Carvedilol Tablet, Film Coated
Product Images NDC 71335-1457

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71335-1457). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph depicting percent mortality over time (months) comparing Carvedilol and placebo. The vertical axis represents percent mortality, ranging from 0 to 30%, and the horizontal axis represents time in months from 0 to 21. Two lines show mortality trends for Carvedilol and placebo groups, with a p-value of 0.0014 indicated near the beginning of the timeline.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A hazard ratio forest plot comparing outcomes across various subgroups including gender, age, race, diabetes status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use. The plot shows point estimates with confidence intervals for each subgroup relative to a hazard ratio of 1.0, indicating relative risk differences among the groups.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph comparing percentage mortality over 24 months between Carvedilol and placebo groups, showing mortality rates on the vertical axis and time in months on the horizontal axis. The graph indicates lower mortality with Carvedilol compared to placebo and includes a p-value of 0.03.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A forest plot depicting hazard ratios with confidence intervals for various patient subgroups related to carvedilol treatment. The subgroups include age, gender, timing post-myocardial infarction, beta-blocker use, Killip class, thrombolytic therapy, PCI status, congestive heart failure, diuretics use, angina, hypertension, diabetes, heart rate, and blood pressure. The plot compares these factors with outcomes, illustrating differences in risk estimates across categories.*
FDA Label Image

Label (Lbl713351457)

Label (Lbl713351457)
Carvedilol 6.25 mg tablet label from Bryant Ranch Prepack, showing comparison to Coreg 6.25 mg tablets by Beximco Pharmaceuticals Limited. The label indicates a quantity of 30 tablets, a space for expiration date, storage instructions at 20°-25°C (68°-77°F), and includes the NDC 71335-1457. The label also includes a barcode and lot number area.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure of Carvedilol, depicting its molecular arrangement including the indole group, hydroxyl group, amine, and methoxyphenyl components as part of its chemical formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.